FRANKLIN LAKES, N.J., March 31, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today was named to Fortune's 2025 list of America's Most Innovative Companies, ranking in the top 25% of companies overall. The list recognizes organizations that excel in developing innovative products, streamlining processes, and cultivating a forward-thinking corporate culture. "As one of the largest manufacturers of medical devices in the world whose products ...

FRANKLIN LAKES, N.J., March 27, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Gregory J. Hayes to its board of directors, effective March 26, 2025. BD appoints Gregory J. Hayes to its board of directors. Hayes, 64, is currently the executive chairman of the board of directors of RTX Corporation, the world's largest aerospace and defense company. He brings more than 30 years of extensive executive expe ...

Becton, Dickinson and Company’s (BDX) , or popularly known as BD, initiated the recall of its infusion pumps last month after customer reports indicated software issues, potentially leading to inaccurate therapy administration. The FDA designated BD’s recall of its infusion pump software as Class I, the most severe classification, last week. While no injuries or fatalities have been reported, the FDA warns that continued use of the affected software could result in serious harm or even death if appropriate ...

Core Viewpoint - Becton, Dickinson and Company (BDX) is advancing its GalaFLEX LITE Scaffold under an Investigational Device Exemption to secure FDA Premarket Approval, targeting the reduction of capsular contracture recurrence in breast revision surgeries [1][4]. Group 1: Product and Market Context - The GalaFLEX LITE Scaffold is designed to address unmet needs in breast reconstruction, aiming to improve patient recovery, safety, and satisfaction [2]. - Capsular contracture (CC) is a common complication in implant-based breast surgeries, affecting 10% to 20% of patients, leading to pain and potential revision surgeries [6]. - The scaffold is a bioabsorbable surgical mesh made from P4HB, which dissolves over time, supporting tissue integration and reducing mechanical stress during healing [10][11]. Group 2: Clinical Study Details - The pivotal STANCE study will enroll at least 250 patients across 40 sites, comparing the scaffold's effectiveness against standard revision surgery without a supportive matrix [9]. - The study aims to demonstrate the safety and effectiveness of the GalaFLEX LITE Scaffold in improving surgical outcomes [7]. Group 3: Financial and Stock Performance - Following the announcement, BDX shares closed flat at $230.23, with a 2.8% decline over the past six months, while the industry grew by 2.8% [3]. - BDX currently has a market capitalization of $66.11 billion and reported an earnings surprise of 15.1% in the last quarter [5]. - The successful implementation of the GalaFLEX LITE Scaffold could enhance demand from surgeons and hospitals, potentially leading to new revenue streams and improved profitability [4].

FRANKLIN LAKES, N.J., March 20, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the first patient treated in an Investigational Device Exemption (IDE) clinical trial intended to advance BD's efforts to achieve Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for the use of GalaFLEX LITE™ Scaffold in decreasing capsular contracture (CC) recurrence during breast revision surgery. BD's Bioabsorbable Ga ...

Core Insights - The Zacks Premium service provides tools for investors to enhance their stock market engagement and confidence, including daily updates, research reports, and stock screens [1] Zacks Style Scores - Zacks Style Scores are indicators that assist investors in selecting stocks likely to outperform the market within 30 days, rated from A to F based on value, growth, and momentum characteristics [2] - The Value Score focuses on identifying undervalued stocks using financial ratios like P/E and Price/Sales to find attractive investment opportunities [3] - The Growth Score emphasizes a company's financial health and future outlook, analyzing projected and historical earnings and cash flow to identify sustainable growth stocks [4] - The Momentum Score helps investors capitalize on price trends by evaluating recent price changes and earnings estimate shifts to identify high-momentum stocks [5] - The VGM Score combines all three Style Scores, providing a comprehensive indicator for investors who utilize multiple investment strategies [6] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to simplify portfolio building, with 1 (Strong Buy) stocks achieving an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [7][8] - Investors are encouraged to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B to maximize potential returns [10] - The direction of earnings estimate revisions is crucial; stocks with lower ranks but high Style Scores may still face downward price pressure [11] Company Spotlight: Becton Dickinson (BDX) - Becton Dickinson, a medical technology company, is currently rated 3 (Hold) with a VGM Score of B, and has shown a 1.4% increase in share price over the past four weeks [12] - Recent upward revisions in earnings estimates by five analysts for fiscal 2025 have raised the Zacks Consensus Estimate to $14.43 per share, with an average earnings surprise of 7.3% [13]

Becton, Dickinson and Company (NYSE:BDX) Citi's 2025 Unplugged Medtech and Life Sciences Access Day November 27, 2025 8:45 AM ET Company Participants Tom Polen – Chairman, Chief Executive Officer and President Chris DelOrefice – Executive Vice President and Chief Financial Officer Conference Call Participants Joanne Wuensch – Citi Joanne Wuensch We're live? Excellent. Hi, I'm Joanne Wuensch, I'm the medical technology analyst here at Citibank and we are in Citi's Unplugged Medtech and Life Sciences Tools Da ...

FRANKLIN LAKES, N.J., Feb. 13, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the following healthcare conferences:Citi's 2025 Unplugged Medtech and Life Sciences Access DayFebruary 27, 20258:45 a.m. Eastern TimeBarclays 27th Annual Global Healthcare ConferenceMarch 11, 20258:30 a.m. Eastern TimeThe live webcasts of BD's presentations can be accessed from the BD investor relations website, investors.bd ...

Activist Commentary: Starboard is a very successful activist investor and has extensive experience helping companies focus on operational efficiency and margin improvement. Starboard also has significant experience with its strategic activism. In 57 prior campaigns where it had a strategic thesis, the firm had a 32.96% return versus 14.61% for the Russell 2000 during the same period. Additionally, Starboard has initiated activist campaigns at 24 prior health-care companies and its average return on these si ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-4802 Becton, Dickinson and Company (Exact name of registrant as specified in its charter) New Jersey 22-0760120 (State or oth ...